Researchers at Stony Brook Cancer Center engineered a therapy combining a natural tumor-suppressing molecule with a standard chemotherapy drug designed to stop non-small cell lung cancer from developing drug resistance, according to Jim Baranski, Executive Director at the Lung Cancer Foundation of America.
Stony Brook Lab Results and Preclinical Findings
In early laboratory models, the newly engineered combination therapy successfully shrank tumors by more than 95%, according to statements shared by Baranski on LinkedIn. While this work remains strictly preclinical, Baranski noted that almost every medical treatment saving lives today passed through this exact foundational stage of being promising yet unproven.
Funding Early-Stage Lung Cancer Research
Bridging the gap between initial laboratory discoveries and clinical trials requires dedicated financial support. The Lung Cancer Foundation of America focuses on funding these early-stage investigative steps, reporting a 13 times return on investment from its supported researchers as of this year.
Did you know?
Frequently Asked Questions
What did the Stony Brook Cancer Center study achieve?
Are these findings currently available to patients?
No. This research is in the early preclinical stage and requires further funding and development before moving toward clinical trials.
What is the role of the Lung Cancer Foundation of America in this work?
The foundation provides critical funding to help promising, unproven laboratory research advance to the next step of scientific validation.
Want to stay updated on the latest breakthroughs in oncology? Subscribe to our newsletter or explore more lung cancer research articles on OncoDaily to join the conversation.
Related reading